clinical trial · NCT04002700
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
Janssen Research & Development, LLC·—·completed·n = 1,234,412
StrokeHaloperidolTypical AntipsychoticsAtypical Antipsychotics
brief summary
The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and did not have dementia to participants aged 65 years and older regardless of dementia status.
started
May 6, 2019
primary completion
May 31, 2019
completion
May 31, 2019
last updated
Jun 25, 2025
official title
Stroke Risk Among Users of Typical vs. Atypical Antipsychotics Stratified by Broad Age Group, a Post-authorization Safety Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol